Advanced Filters
noise
Found 645 clinical trials
S Site Contact

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

This phase Ib trial tests the safety, side effects, and best dose of leflunomide in combination with gemcitabine in treating patients with pancreatic cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and cannot be removed by …

18 years of age All Phase 1
Y Ying Yang, MD

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

The purpose of this study is to evaluate the efficacy of chemotherapy plus radiotherapy to patients with CA19-9-elevated Advanced Pancreatic Cancer who are not refractory to chemotherapy.

18 - 80 years of age All Phase 3
D D D

DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional method when a tumor is categorized as borderline resectable pancreatic cancer. UAB radiological research team has been studying a …

19 years of age All Phase N/A
J J.W. Wilmink, Dr.

Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5)

Since patients with borderline resectable pancreatic cancer (BRPC) have a limited life expectancy, it is important to improve treatment strategies. Therefore, the objective of this study is to investigate whether neoadjuvant triple treatment chemotherapy, immunotherapy and radiotherapy, followed by surgery and chemotherapy and immunotherapy survival in patients with BRPC.

18 years of age All Phase 1/2

Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer

The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of Advanced Pancreatic Cancer. The secondary objective was to observe the preliminary efficacy of mRNA-0217/S001 personalized tumor vaccine in the …

18 years of age All Phase N/A

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are: Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab …

18 - 75 years of age All Phase 2
R Rui Liu

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.

18 - 75 years of age All Phase 2
Y Ying Yang, MD

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer

The purpose of this study is to evaluate the efficacy of mFOLFIRINOX plus radiotherapy to Patients with CA19-9-normal Advanced Pancreatic Cancer.

18 - 80 years of age All Phase 2
W Wenbo Meng, MD,PhD

Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer

This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.

18 - 85 years of age All Phase N/A

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be eligible to enrol. The investigators hypothesize the anticancer activity of low dose OXIRI (LD-OXIRI) regimen comprising of metronomic oxaliplatin (O) and metronomic capecitabine …

21 - 99 years of age All Phase 2

Simplify language using AI